With a new class of PET radiopharmaceuticals targeting the prostate-specific membrane antigen (PSMA), it has become feasible to detect recurrent or metastatic prostate cancer that is otherwise occult on conventional imaging modalities (6–9). This evidence concerns the gene FOLH1 and metastatic prostate carcinoma.